Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

December 2, 2016

Most Mesothelioma Cases in China Aren’t Linked to Asbestos Exposure, Research Shows

News

China has a unique prevalence of different mesothelioma types and an unusual incidence of the disease in women, according to a research letter published in JAMA Oncology. The research letter, titled, “Association ... Read more

December 1, 2016

Merck to Present New Data on Keytruda in Mesothelioma, Other Thoracic Cancers

News

Merck announced that new data from the company’s anti-PD-1 cancer drug Keytruda (pembrolizumab) will be presented at the upcoming 17th World Conference on Lung Cancer (WCLC), hosted by the International Association for ... Read more

November 22, 2016November 22, 2016

Clinical Trials of Cancer Vaccine Using Listeria Again Enrolling Patients After FDA Lifts Hold

News

The U.S. Food and Drug Administration (FDA) has lifted a partial hold placed on all Aduro’s clinical trials evaluating the LADD technology platform, a new Listeria-based cancer vaccine. These studies, including one in ... Read more

November 18, 2016

Treatment Trio for Mesothelioma Is Safe, Improves Patients’ Survival Rates, According to Trial Data

News

Combining Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, with standard chemotherapy treatments Alimta (pemetrexed) and Platinol (cisplatin) or Paraplatin (carboplatin) may be a ... Read more

November 11, 2016November 11, 2016

Targovax Granted European Patent for Vaccine to Treat Mesothelioma, Now in Clinical Trial

News

Targovax has been granted a European patent for its lead product ONCOS-102, a cancer vaccine that is being clinically evaluated in mesothelioma, with tests planned for other solid tumors. The composition of matter patent, ... Read more

October 31, 2016October 31, 2016

FDA Pauses Enrollment in Trials Testing Listeria as Therapy for Mesothelioma and Other Cancers

News

The U.S. Food and Drug Administration (FDA) has placed a partial hold on all clinical trials evaluating the LADD (Listeria-based immunotherapy construct) technology platform, pausing new patient enrollment. Those already undergoing therapy will ... Read more

October 26, 2016

Experimental Mesothelioma Therapy May Boost Tumor Immune Surveillance

News

ADI-PEG 20, a drug that depletes arginine from the body, is under clinical trials for a number of cancers, including mesothelioma, due to its strong anti-cancer activity. But a new ... Read more

October 17, 2016May 16, 2017

Promising Approach Against Mesothelioma Involves Inhibiting 2 Proteins

News

Simultaneous inhibition of two proteins, FAK and MDM2, may have therapeutic applications against mesothelioma. A recent study showed that the proteins prevent malignant cells from activating mechanisms involved in cell death, and activate those involved ... Read more

October 5, 2016

Rosetta Receives 2 Patent Allowances, 1 for Mesothelioma Diagnostic

News

Rosetta Genomics, a company that develops microRNA-based diagnostics, has added two new patent allowances to its intellectual property. A patent allowance is issued by a regulatory entity (U.S. Patent and ... Read more